Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Nuwellis Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.23 (market cap $3.62B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: iShares MSCI United Kingdom (FTSE) is far larger — about 1645.5× Nuwellis Inc's market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Nuwellis Inc for 26 Days on average.
| EWU | NUWE | |
|---|---|---|
Market Cap | $3.62B | $2.20M |
Volume | 923,896 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $146.65 |
52-Week Low | $41.34 | $0.68 |
Typical Hold Time | 46 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, is trading at $45.93, down 0.95% amid broader market pressures. Technical indicators show a bearish trend with moving averages signaling sell pressure, though RSI levels suggest potential oversold conditions. The fund faces headwinds from UK economic concerns including rising gilt yields and inflation pressures, while recent government housing initiatives provide some sector-specific support.
The outlook remains cautious as UK economic vulnerabilities and rising borrowing costs weigh on sentiment. Investment opportunity exists for long-term investors seeking UK exposure at discounted levels, though near-term risks include persistent inflation and political uncertainty surrounding the upcoming budget announcement.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
